

Special Issue

Biomarkers and Clinical Research in Eating Disorders

Message from the Guest Editor

Eating disorders are severe and disabling disorders affecting individuals of all ages, most frequently commencing in adolescence. The treatment success rates are around 50%, and treatment resistance occurs in 20%. Recent genetic research in anorexia nervosa points to genetic associations with, for example, hyperlipidemia, diabetes, schizophrenia, and OCD, laying the foundation for an improved understanding of the nature of the diseases. However, further research is needed in biology, biomarker and clinical research to advance the field towards improved treatments. Cutting-edge research in recent years, especially genome-wide association studies, has raised hopes of determining the underlying biology of eating disorders. One example is the recent advances in blood-based biomarkers such as increases in cytokines in anorexia nervosa. The aim of this Special Issue is to present research on the psychological and biological pathologies, novel outcomes, or clinical characteristics of eating disorders that may provide clues for improved treatment. We invite original publications, systematic reviews, and case series.

Guest Editor

Dr. Jan Magnus Sjøgren

Institute for Clinical Science, Department of Psychiatry, Umeå University, 901 85 Umeå, Sweden

Deadline for manuscript submissions

closed (22 January 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/74699

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).